INFI Annual SG&A
$13.46 M
-$711.00 K-5.02%
31 December 2022
Summary:
As of January 21, 2025, INFI annual selling, general & administrative expenses is $13.46 million, with the most recent change of -$711.00 thousand (-5.02%) on December 31, 2022. During the last 3 years, it has fallen by -$826.00 thousand (-5.78%).INFI Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Quarterly SG&A
$3.75 M
-$2.19 M-36.84%
30 June 2023
Summary:
As of January 21, 2025, INFI quarterly selling, general & administrative expenses is $3.75 million, with the most recent change of -$2.19 million (-36.84%) on June 30, 2023. Over the past year, it has increased by +$259.00 thousand (+7.41%).INFI Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI TTM SG&A
-$3.45 B
-$40.95 M-1.20%
30 June 2023
Summary:
As of January 21, 2025, INFI TTM selling, general & administrative expenses is -$3.45 billion, with the most recent change of -$40.95 million (-1.20%) on June 30, 2023. Over the past year, it has dropped by -$3.46 billion (-24234.33%).INFI TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.0% | +7.4% | -10000.0% |
| 3 y3 years | -5.8% | +27.8% | -10000.0% |
| 5 y5 years | -37.7% | +10.9% | -10000.0% |
INFI Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -68.1% | -76.1% | -7652.8% |
Infinity Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $3.75 M(-36.8%) | $15.99 M(+1.6%) |
| Mar 2023 | - | $5.94 M(+113.0%) | $15.73 M(+16.8%) |
| Dec 2022 | $13.46 M(-5.0%) | $2.79 M(-20.3%) | $13.46 M(-3.4%) |
| Sept 2022 | - | $3.50 M(+0.2%) | $13.94 M(-2.4%) |
| June 2022 | - | $3.50 M(-4.9%) | $14.28 M(-0.0%) |
| Mar 2022 | - | $3.68 M(+12.7%) | $14.28 M(+0.8%) |
| Dec 2021 | $14.17 M(+14.1%) | $3.26 M(-15.2%) | $14.17 M(+0.3%) |
| Sept 2021 | - | $3.85 M(+10.0%) | $14.14 M(+6.9%) |
| June 2021 | - | $3.50 M(-1.9%) | $13.22 M(+4.4%) |
| Mar 2021 | - | $3.57 M(+10.5%) | $12.66 M(+1.9%) |
| Dec 2020 | $12.42 M(-13.1%) | $3.23 M(+10.1%) | $12.42 M(-2.0%) |
| Sept 2020 | - | $2.93 M(-0.2%) | $12.67 M(-5.3%) |
| June 2020 | - | $2.94 M(-11.6%) | $13.38 M(-5.9%) |
| Mar 2020 | - | $3.32 M(-4.5%) | $14.21 M(-0.5%) |
| Dec 2019 | $14.29 M(+0.3%) | $3.48 M(-4.4%) | $14.29 M(-2.3%) |
| Sept 2019 | - | $3.64 M(-3.4%) | $14.62 M(+1.4%) |
| June 2019 | - | $3.77 M(+11.0%) | $14.42 M(+2.7%) |
| Mar 2019 | - | $3.40 M(-10.9%) | $14.04 M(-1.5%) |
| Dec 2018 | $14.25 M(-34.1%) | $3.81 M(+10.8%) | $14.25 M(-4.4%) |
| Sept 2018 | - | $3.44 M(+1.7%) | $14.90 M(-6.7%) |
| June 2018 | - | $3.39 M(-6.1%) | $15.96 M(-15.0%) |
| Mar 2018 | - | $3.61 M(-19.3%) | $18.78 M(-13.1%) |
| Dec 2017 | $21.61 M(-48.8%) | $4.47 M(-0.8%) | $21.61 M(-16.0%) |
| Sept 2017 | - | $4.50 M(-27.4%) | $25.72 M(-9.2%) |
| June 2017 | - | $6.21 M(-3.6%) | $28.33 M(-25.1%) |
| Mar 2017 | - | $6.44 M(-24.9%) | $37.82 M(-10.4%) |
| Dec 2016 | $42.22 M(+13.9%) | $8.57 M(+20.4%) | $42.22 M(-1.8%) |
| Sept 2016 | - | $7.12 M(-54.6%) | $43.00 M(-5.8%) |
| June 2016 | - | $15.69 M(+44.8%) | $45.63 M(+16.0%) |
| Mar 2016 | - | $10.84 M(+15.9%) | $39.35 M(+6.2%) |
| Dec 2015 | $37.06 M(+26.6%) | $9.35 M(-4.1%) | $37.07 M(+5.6%) |
| Sept 2015 | - | $9.75 M(+3.7%) | $35.10 M(+5.1%) |
| June 2015 | - | $9.41 M(+10.1%) | $33.38 M(+7.6%) |
| Mar 2015 | - | $8.55 M(+15.8%) | $31.03 M(+6.0%) |
| Dec 2014 | $29.29 M(+4.9%) | $7.38 M(-8.2%) | $29.29 M(+3.1%) |
| Sept 2014 | - | $8.04 M(+14.0%) | $28.39 M(+2.6%) |
| June 2014 | - | $7.06 M(+3.7%) | $27.67 M(+1.4%) |
| Mar 2014 | - | $6.80 M(+4.8%) | $27.29 M(-2.2%) |
| Dec 2013 | $27.92 M(+0.1%) | $6.49 M(-11.3%) | $27.92 M(-2.2%) |
| Sept 2013 | - | $7.32 M(+9.6%) | $28.54 M(+3.7%) |
| June 2013 | - | $6.67 M(-10.2%) | $27.51 M(-3.5%) |
| Mar 2013 | - | $7.43 M(+4.5%) | $28.50 M(+2.2%) |
| Dec 2012 | $27.88 M(+22.7%) | $7.11 M(+13.0%) | $27.88 M(+4.0%) |
| Sept 2012 | - | $6.29 M(-17.9%) | $26.82 M(+3.2%) |
| June 2012 | - | $7.67 M(+12.5%) | $25.99 M(+5.4%) |
| Mar 2012 | - | $6.81 M(+12.7%) | $24.66 M(+8.5%) |
| Dec 2011 | $22.72 M | $6.04 M(+10.5%) | $22.72 M(-0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $5.47 M(-13.6%) | $22.77 M(+2.0%) |
| June 2011 | - | $6.33 M(+29.8%) | $22.31 M(+5.3%) |
| Mar 2011 | - | $4.88 M(-19.9%) | $21.20 M(+0.6%) |
| Dec 2010 | $21.07 M(+8.3%) | $6.09 M(+21.4%) | $21.07 M(+11.7%) |
| Sept 2010 | - | $5.01 M(-3.9%) | $18.85 M(+2.4%) |
| June 2010 | - | $5.22 M(+9.8%) | $18.41 M(-2.5%) |
| Mar 2010 | - | $4.75 M(+22.6%) | $18.88 M(-3.0%) |
| Dec 2009 | $19.46 M(+15.6%) | $3.87 M(-15.2%) | $19.46 M(-8.2%) |
| Sept 2009 | - | $4.57 M(-19.6%) | $21.18 M(+3.9%) |
| June 2009 | - | $5.68 M(+6.6%) | $20.39 M(+10.9%) |
| Mar 2009 | - | $5.33 M(-4.9%) | $18.40 M(+9.3%) |
| Dec 2008 | $16.84 M(+20.0%) | $5.60 M(+48.2%) | $16.84 M(+6.3%) |
| Sept 2008 | - | $3.78 M(+2.7%) | $15.84 M(+5.9%) |
| June 2008 | - | $3.68 M(-2.4%) | $14.96 M(+3.1%) |
| Mar 2008 | - | $3.77 M(-18.1%) | $14.51 M(+3.4%) |
| Dec 2007 | $14.03 M(+48.3%) | $4.60 M(+58.8%) | $14.03 M(+7.3%) |
| Sept 2007 | - | $2.90 M(-10.4%) | $13.08 M(+3.5%) |
| June 2007 | - | $3.24 M(-1.7%) | $12.64 M(+17.2%) |
| Mar 2007 | - | $3.29 M(-9.8%) | $10.78 M(+14.0%) |
| Dec 2006 | $9.46 M(+71.1%) | $3.65 M(+48.9%) | $9.46 M(+30.8%) |
| Sept 2006 | - | $2.45 M(+77.1%) | $7.23 M(+16.9%) |
| June 2006 | - | $1.39 M(-29.8%) | $6.19 M(-16.6%) |
| Mar 2006 | - | $1.97 M(+38.7%) | $7.42 M(-24.4%) |
| Dec 2005 | $5.53 M(+4.5%) | $1.42 M(+1.1%) | $9.82 M(+250.0%) |
| Sept 2005 | - | $1.41 M(-46.2%) | $2.81 M(-45.2%) |
| June 2005 | - | $2.62 M(-40.1%) | $5.12 M(-16.0%) |
| Mar 2005 | - | $4.37 M(-178.2%) | $6.10 M(+15.3%) |
| Dec 2004 | $5.29 M(-62.1%) | -$5.59 M(-250.2%) | $5.29 M(-64.7%) |
| Sept 2004 | - | $3.72 M(+3.5%) | $14.98 M(+2.5%) |
| June 2004 | - | $3.60 M(+1.0%) | $14.62 M(+1.4%) |
| Mar 2004 | - | $3.56 M(-13.2%) | $14.42 M(+3.5%) |
| Dec 2003 | $13.96 M(+13.8%) | $4.10 M(+22.0%) | $13.94 M(+13.6%) |
| Sept 2003 | - | $3.36 M(-1.1%) | $12.27 M(-1.3%) |
| June 2003 | - | $3.40 M(+10.6%) | $12.43 M(+3.0%) |
| Mar 2003 | - | $3.07 M(+26.1%) | $12.08 M(-1.6%) |
| Dec 2002 | $12.27 M(+11.4%) | $2.44 M(-30.8%) | $12.27 M(-3.2%) |
| Sept 2002 | - | $3.52 M(+15.9%) | $12.67 M(+7.3%) |
| June 2002 | - | $3.04 M(-7.0%) | $11.81 M(+2.8%) |
| Mar 2002 | - | $3.27 M(+15.0%) | $11.49 M(+4.3%) |
| Dec 2001 | $11.02 M(+31.0%) | $2.84 M(+6.6%) | $11.02 M(+4.1%) |
| Sept 2001 | - | $2.66 M(-2.0%) | $10.58 M(+3.4%) |
| June 2001 | - | $2.72 M(-2.9%) | $10.24 M(+5.6%) |
| Mar 2001 | - | $2.80 M(+16.3%) | $9.69 M(+15.2%) |
| Dec 2000 | $8.41 M(+89.5%) | $2.40 M(+3.7%) | $8.41 M(+40.0%) |
| Sept 2000 | - | $2.32 M(+6.8%) | $6.01 M(+62.8%) |
| June 2000 | - | $2.17 M(+42.9%) | $3.69 M(+142.9%) |
| Mar 2000 | - | $1.52 M | $1.52 M |
| Dec 1999 | $4.44 M | - | - |
FAQ
- What is Infinity Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals annual SG&A year-on-year change?
- What is Infinity Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals quarterly SG&A year-on-year change?
- What is Infinity Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals TTM SG&A year-on-year change?
What is Infinity Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of INFI is $13.46 M
What is the all time high annual SG&A for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high annual selling, general & administrative expenses is $42.22 M
What is Infinity Pharmaceuticals annual SG&A year-on-year change?
Over the past year, INFI annual selling, general & administrative expenses has changed by -$711.00 K (-5.02%)
What is Infinity Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of INFI is $3.75 M
What is the all time high quarterly SG&A for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $15.69 M
What is Infinity Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, INFI quarterly selling, general & administrative expenses has changed by +$259.00 K (+7.41%)
What is Infinity Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of INFI is -$3.45 B
What is the all time high TTM SG&A for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high TTM selling, general & administrative expenses is $45.63 M
What is Infinity Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, INFI TTM selling, general & administrative expenses has changed by -$3.46 B (-24234.33%)